EU · EudraLex Vol.4
EU GMP Part I, Chapter 6
Quality Control
Status of the document: Revision
Table of contents
- PrinciplePrinciple
- 6.1Each holder of a manufacturing authorisation should have a Quality Control Department. This department should be independent from other dep…
- 6.2The principal duties of the head of Quality Control are summarised in Chapter 2. The Quality Control Department as a whole will also have o…
- 6.3Finished product assessment should embrace all relevant factors, including production conditions, results of in-process testing, a review o…
- 6.4Quality Control personnel should have access to production areas for sampling and investigation as appropriate.
- 6.5Control laboratory premises and equipment should meet the general and specific requirements for Quality Control areas given in Chapter 3. L…
- 6.6The personnel, premises, and equipment in the laboratories should be appropriate to the tasks imposed by the nature and the scale of the ma…
- 6.7Laboratory documentation should follow the principles given in Chapter 4. An important part of this documentation deals with Quality Contro…
- 6.8Any Quality Control documentation relating to a batch record should be retained following the principles given in chapter 4 on retention of…
- 6.9Some kinds of data (e.g. tests results, yields, environmental controls) should be recorded in a manner permitting trend evaluation. Any out…
- 6.10In addition to the information which is part of the batch documentation, other raw data such as laboratory notebooks and/or records should…
- 6.11The sample taking should be done and recorded in accordance with approved written procedures that describe: i. The method of sampling; ii.…
- 6.12Samples should be representative of the batch of materials or products from which they are taken. Other samples may also be taken to monito…
- 6.13Sample containers should bear a label indicating the contents, with the batch number, the date of sampling and the containers from which sa…
- 6.14Further guidance on reference and retention samples is given in Annex 19.
- 6.15Testing methods should be validated. A laboratory that is using a testing method and which did not perform the original validation, should…
- 6.16The results obtained should be recorded. Results of parameters identified as quality attribute or as critical should be trended and checked…
- 6.17The tests performed should be recorded and the records should include at least the following data: i. Name of the material or product and,…
- 6.18All the in-process controls, including those made in the production area by production personnel, should be performed according to methods…
- 6.19Special attention should be given to the quality of laboratory reagents, solutions, glassware, reference standards and culture media. They…
- 6.20Reference standards should be established as suitable for their intended use. Their qualification and certification as such should be clear…
- 6.21Laboratory reagents, solutions, reference standards and culture media should be marked with the preparation and opening date and the signat…
- 6.22Where necessary, the date of receipt of any substance used for testing operations (e.g. reagents, solutions and reference standards) should…
- 6.23Culture media should be prepared in accordance with the media manufacturer’s requirements unless scientifically justified. The performance…
- 6.24Used microbiological media and strains should be decontaminated according to a standard procedure and disposed of in a manner to prevent th…
- 6.25Animals used for testing components, materials or products, should, where appropriate, be quarantined before use. They should be maintained…
- 6.26After marketing, the stability of the medicinal product should be monitored according to a continuous appropriate programme that will permi…
- 6.27The purpose of the on-going stability programme is to monitor the product over its shelf life and to determine that the product remains, an…
- 6.28This mainly applies to the medicinal product in the package in which it is sold, but consideration should also be given to the inclusion in…
- 6.29The on-going stability programme should be described in a written protocol following the general rules of Chapter 4 and results formalised…
- 6.30The protocol for an on-going stability programme should extend to the end of the shelf life period and should include, but not be limited t…
- 6.31The protocol for the on-going stability programme can be different from that of the initial long-term stability study as submitted in the m…
- 6.32The number of batches and frequency of testing should provide a sufficient amount of data to allow for trend analysis. Unless otherwise jus…
- 6.33In certain situations, additional batches should be included in the on-going stability programme. For example, an on-going stability study…
- 6.34Results of on-going stability studies should be made available to key personnel and, in particular, to the Qualified Person(s). Where on-go…
- 6.35Out of specification or significant atypical trends should be investigated. Any confirmed out of specification result, or significant negat…
- 6.36A summary of all the data generated, including any interim conclusions on the programme, should be written and maintained. This summary sho…
- 6.37Prior to transferring a test method, the transferring site should verify that the test method(s) comply with those as described in the Mark…
- 6.38The transfer of testing methods from one laboratory (transferring laboratory) to another laboratory (receiving laboratory) should be descri…
- 6.39The transfer protocol should include, but not be limited to, the following parameters: i. Identification of the testing to be performed and…
- 6.40Deviations from the protocol should be investigated prior to closure of the technical transfer process. The technical transfer report shoul…
- 6.41Where appropriate, specific requirements described in others European Guidelines, should be addressed for the transfer of particular testin…
Cover page and contents (original)
Ref. Ares(2014)968036 - 28/03/2014
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL
Health systems and products Medicinal products – quality, safety and efficacy
Brussels, 28 March 2014
EudraLex
The Rules Governing Medicinal Products in the European Union
Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use
Part 1 Chapter 6: Quality Control
Legal basis for publishing the detailed guidelines: Article 47 of Directive 2001/83/EC on the Community code relating to medicinal products for human use and Article 51 of Directive 2001/82/EC on the Community code relating to veterinary medicinal products. This document provides guidance for the interpretation of the principles and guidelines of good manufacturing practice (GMP) for medicinal products as laid down in Directive 2003/94/EC for medicinal products for human use and Directive 91/412/EEC for veterinary use.
Status of the document: Revision
Reasons for changes: Inclusion of a new section on technical transfer of testing methods and other items such as Out Of Specification results.
Deadline for coming into operation: 1 October 2014 Commission Européenne, B-1049 Bruxelles / Europese Commissie, B-1049 Brussel – Belgium. Telephone: (32-2) 299 11 11
Source: European Commission, DG SANTE · © European Union. Reuse is authorised provided the source is acknowledged (Commission Decision 2011/833/EU on the reuse of Commission documents). · retrieved 2026-11-15